---
title: "NSABP B-35"
slug: "nsabp-b"
date: "2023-10-19"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[DCIS and LCIS]]

# NSABP B-35

1. Design: Randomized controlled trial.
2. Number of patients: 3104 patients were entered and randomized, with follow-up information available on 3083 patients for OS and 3077 for all other disease-free endpoints.
3. Patients characteristics: Not reported.
4. Agents: Tamoxifen (T) and anastrozole (A), both aromatase inhibitors.
5. Treatment line: Adjuvant therapy after surgery.
6. Trial Name/NCT Number: Not reported.
7. Comparison of two groups in a markdown table:

| Group/Outcome | Tamoxifen | Anastrozole |
| --- | --- | --- |
| 10-year estimate for breast cancer-free interval (BCFI) | 89.1% (95% CI, 86.8-91.0) | 93.1% (95% CI, 91.5-94.5) |
| Hazard ratio (HR) for BCFI | 0.73 (95% CI, 0.56-0.96) | Not reported |
| P value | 0.0234 | Not reported |
| 10-year estimate for disease-free survival (DFS) | 77.9% (95% CI, 75.0-80.6) | 82.7% (95% CI, 80.4-84.7) |
| HR for DFS | 0.89 (95% CI, 0.75-1.07) | Not reported |
| P value | 0.21 | Not reported |
| 10-year estimate for overall survival (OS) | 92.1% (95% CI, 90.1-93.7) | 92.5% (95% CI, 90.8-93.9) |
| HR for OS | 1.11 (95% CI, 0.83-1.48) | Not reported |
| P value | 0.48 | Not reported |
| Deaths due to breast cancer | 8 | 5 |
| Cases of invasive breast cancer | 69 | 43 |
| HR for contralateral breast cancers | 0.64 (95% CI, 0.43-0.96) | Not reported |
| P value | 0.0322 | Not reported |

Note: Specific patient characteristics, such as age or menopausal status, are not provided. The trial name and NCT number are not reported.
